Peng Jiao, PhD, CEO, of the Boston Institute of Biotechnology (BIB), outlined the company’s biomanufacturing expansions at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

BIB and BiBo Pharma (BiBo), an affiliate, were respectively founded by Dr. Jiao in 2014 and 2017. The CDMO has facilities in Southborough, Massachusetts, and Shanghai, China, with a focus on biologics drug substance and drug-product manufacturing. The company provides GMP services for microbial and mammalian-derived biologics and gene and cell therapy therapeutics.

Jiao reported on the company’s successful biomanufacturing capacity expansion of over 420,000 liters at its site in Shanghai between February 2025 and February 2026, The scaling was driven by BIB & BiBo’s proprietary engineering technology, PanFlex Engineering System, which seeks to reduce capital expenditure costs and timelines while improving costs per unit yield.

The company is also adding an additional 220,000L of new capacity in Shanghai, slated to come online in 2026, which includes 4 x 50,000 L plus 1 x 20,000 L of mammalian capacity. The company has an eventual goal of scaling toward 1 million liters of global manufacturing capacity by 2030.